Masimo Corporation (NASDAQ:MASI), a global medical technology company, develops, manufactures and markets noninvasive patient monitoring products worldwide. The company offers Signal Extraction Technology ("SET"), which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. MASI recently introduced the first-and-only FDA-approved technology that continuously measures blood hemoglobin without a painful needle stick. This technology is expected to open new markets and significantly expand the company's growth opportunities in the near future.
Masimo's stock has created a 52-week low of $19 and a 52-week high of $29. Currently it is hovering around the 52-week high and I expect that MASI will reach at least $36 in the next twelve
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|